5 minute read
Jan. 12, 2024

Moving Targets: Key Clinical Readouts on NaV1.8, BTK, & More From December 2023


There were several key clinical readouts in Dec. 2023 for small molecules in areas ranging from non-opioid pain management to sickle cell disease. While most results were positive, one pivotal trial led to a program discontinuation. This roundup highlights key data recently reported for selected molecules targeting NaV1.8, BTK, and more.



Other articles you may be interested in